Novo Nordisk A/s logo

Novo Nordisk A/s(OTC) NONOF

Market Cap$166.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+140%
5 Year-14%
1 Year-26%
1 Month-7%
$39.48
+4.74%
+1.78Today
Novo Nordisk A/s last closing stock price
MetricPriceDate
Last closeUSD 39.482026-10-15
Novo Nordisk A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.12%USD 38.282026-10-08
1 month-6.93%USD 42.422026-09-15
3 month-21.19%USD 50.092026-07-17
Year to date-18.86%USD 48.652025-12-31
1 year-26.06%USD 53.392025-10-15
3 year-57.36%USD 92.592023-10-16
5 year-14.45%USD 46.142021-10-15
Since inception+140.49%USD 15.672003-07-31

Novo Nordisk A/s Financials at a Glance

Market Cap

$166.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 329.25B

Net Income (TTM)

DKK 116.38B

EPS (TTM)

$4.09

P/E Ratio

9.20

Dividend

$1.80

Beta (Volatility)

0.49 (Low)

Price

$39.48

Volume

83,965

Open

$36.45

Previous Close

$39.48

Daily Range

$36.45 - $40.24

52-Week Range

$34.00 - $64.75

Estimated Earnings Date

Nov 4, 2026

NONOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Nordisk A/s

Novo Nordisk A/S is a leading global pharmaceutical company focused on the discovery, development, production, and distribution of a diverse range of medicinal products. Established in 1923 and headquartered in Bagsvaerd, Denmark, the company operates primarily in two segments: Diabetes and Obesity Care, and Biopharmaceuticals.

Products and Services
  • Insulin preparations and GLP-1 receptor agonists
  • Oral antidiabetic medications and weight management therapies
  • Specialized treatments for hemophilia and hormone replacement therapy
Growth Outlook
  • Strong demand for diabetes and obesity care products drives revenue growth
  • Strategic collaborations enhance research and development capabilities
  • Focus on innovative therapies positions the company for future expansion
Financial Highlights
  • Q2 2026 revenue of 78.49 billion DKK, reflecting robust sales performance
  • Net income of 20.99 billion DKK in Q2 2026, showcasing strong profitability
  • Trailing twelve months (TTM) net profit margin of 35.35%, indicating operational efficiency
Novo Nordisk A/S has established itself as a key player in the pharmaceutical industry, particularly in diabetes and obesity care. The company's commitment to innovation and strategic partnerships enhances its ability to deliver effective treatments. Recent financial performance highlights a strong revenue trajectory and profitability, making it an attractive option for potential investors. The focus on research and development, coupled with a solid product portfolio, positions Novo Nordisk for sustained growth in the evolving healthcare landscape.
AI Generated • Oct 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

68,794

CEO

Maziar Mike Doustdar

Website

www.novonordisk.com

Headquarters

Bagsvaerd, CR 2880, DK

NONOF Financials

Key Financial Metrics (TTM)

Gross Margin

80.65%

Operating Margin

43.13%

Net Income Margin

35.35%

Return on Equity

59.09%

Return on Capital

40.64%

Return on Assets

19.57%

Earnings Yield

10.87%

Dividend Yield

4.78%

Payout Ratio

44.64%

Stock Overview

Market Cap

$166.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.42B

Volume

83.97K

Avg. Volume

120.81K

Financials (TTM)

Gross Profit

DKK 265.68B

Operating Income

DKK 142.10B

EBITDA

DKK 178.95B

Operating Cash Flow

DKK 132.99B

Capital Expenditure

-DKK 56.86B

Free Cash Flow

DKK 76.14B

Cash & ST Invst.

DKK 44.98B

Total Debt

DKK 140.13B

Novo Nordisk A/s Performance Analysis

Novo Nordisk A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 24,998,461,07711.7%
20232023-12-31DKK 33,700,297,29934.8%
20242024-12-31DKK 42,115,001,36325.0%
20252025-12-31DKK 46,735,785,02911.0%
Novo Nordisk A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.4%
Q42025-12-315.3%
Q12026-03-3122.6%
Q22026-06-30-18.9%
Novo Nordisk A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK 1.734.7%
20232023-12-31DKK 2.7056.5%
20242024-12-31DKK 3.2821.5%
20252025-12-31DKK 3.486.1%
Novo Nordisk A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-24.5%
Q42025-12-3134.0%
Q12026-03-3180.9%
Q22026-06-30-56.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 78.49B

+2.1%

Gross Profit

DKK 61.39B

-4.1%

Gross Margin

78.21%

N/A

Market Cap

$166.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.42M

N/A

Employees

68,794

N/A

Net Income

DKK 20.99B

-20.8%

EBITDA

DKK 38.68B

-11.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 44.98B

+137.6%

Total Debt

DKK 140.13B

+41.2%

Accounts Receivable

DKK 108.51B

+26.4%

Inventory

DKK 51.35B

+12.5%

Long Term Debt

DKK 121.79B

+39.5%

Short Term Debt

DKK 18.33B

+53.2%

Return on Assets

19.57%

N/A

Return on Invested Capital

39.93%

N/A

Free Cash Flow

DKK 42.40B

+73.0%

Operating Cash Flow

DKK 55.20B

+35.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PFEPfizer Inc.
$29.44+0.79%
AZN.LAstraZeneca PLC
£126.98+3.24%
BMYBristol-Myers Squibb Company
$60.57+2.18%
AMGNAmgen Inc.
$434.03+1.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About NONOF

What is the current price of Novo Nordisk A/s?

Novo Nordisk A/s is trading at $39.48 per share.

What is the 52-week range for Novo Nordisk A/s?

Over the past 52 weeks, Novo Nordisk A/s has traded between $34.00 and $64.75.

How much debt does Novo Nordisk A/s have?

As of the most recent reporting period, Novo Nordisk A/s reported total debt of DKK 21.43B.

How much cash does Novo Nordisk A/s have on hand?

Novo Nordisk A/s reported DKK 6.80B in cash and cash equivalents in its most recent financial results.

What is Novo Nordisk A/s’s dividend yield?

Novo Nordisk A/s currently has a dividend yield of 4.78%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services